Back to the main directory
Company Analysis / Equity
- GOVX: On track to advance its HIV vaccine programs--Outperform by Zacks
- GOVX: Positive data reported of GOVX-B11 Phase I trial, balance sheet boosted with new financing, on track to advance its HIV vaccine programs--Outperform by Zacks
- GOVX: exited 3Q13 with reasonable balance sheet, on track to advance its HIV vaccine programs--Outperform by Zacks
- MRLB: Game Changer For Hyperhidrosis? No Sweat! by Zacks
- OPNT: Initiating Coverage of Opiant Pharmaceuticals: Developing Treatments for Substance Use, Addictive, and Eating Disorders by Zacks
- OPNT: Receives $13.7M From Monetizing NARCAN® Nasal Spray Royalties by Zacks
- PBIO: Another strong quarter financials for 2Q14, expecting continued revenue growth in fiscal 2014; valuation very attractive---Outperform. by Zacks
- PBIO: Balance sheet boosted, partnership with SCIEX will enhance product sales, valuation very attractive---Buy by Zacks
- PBIO: Breakthrough PCT-SWATH technology presented; another strong quarter financials for 2Q14, expecting continued revenue growth in fiscal 2014; valuation very attractive---Outperform by Zacks
- PBIO: Just reported better than expected financials for 3Q15, expecting significant revenue growth in 2015 and beyond; valuation very attractive---Buy by Zacks
- PBIO: Record product sales for 1Q14, expecting continued revenue growth in fiscal 2014; valuation very attractive--- Outperform. by Zacks
- PBIO: Record revenue reported for 2014, expecting continued revenue growth in 2015 and beyond; valuation very attractive---Buy by Zacks
- PBIO: revenue increased in 1Q16, great achievements in PIPE financing, partnership with SCIEX will enhance product sales, valuation very attractive by Zacks
- PBIO: reported record revenue for 3Q13, total revenue is expected to surpass $1.5 million in 2013; valuation very attractive--- Outperform. by Zacks
- Raising Estimates Following Strong Third Quarter by Zacks
- Record First Quarter EPS Driven by Strong Growth in the Merchant Card, Cash Flow, and Mortgage Banking Businesses by Zacks
- Record Third Quarter EPS and Another Dividend Increase by Zacks
- Second Quarter Results by Zacks
- Strong financials for 4Q13 and 2013, expecting continued revenue growth in fiscal 2014; valuation very attractive--- Outperform. by Zacks
- Third Quarter Results by Zacks
- Third Quarter Results by Zacks
- Record First Quarter EPS Leads to Increased 2013 Estimate by Zacks
- $1MM Non-Dilutive Financing by Zacks
- $2MM Add'l Financing, CEO Hired by Zacks
- Aggressive Commercialization Initiatives Will Boost Sales For 2012 by Zacks
- GOVX: Positive data reported for GOVX-B11 Phase I trial, on track to advance its HIV vaccine programs--Outperform by Zacks
- On track to advance its HIV vaccine programs by Zacks
- Initiating Coverage by Zacks
- Multiple clinical programs progress well and new vaccine/drug combination trial adds value to the Company by Zacks
- OPNT: Licenses Heroin Vaccine From NIDA; NARCAN Nasal Spray Approved by Health Canada… by Zacks
- 2Q13 revenue continued to grow; total revenue expected to surpass $1.5 million in 2013; valuation very attractive. by Zacks
- PBIO: Another strong quarter for 2Q15, expecting significant revenue growth in 2015 and beyond; valuation very attractive---Buy by Zacks
- PBIO: Balance sheet boosted, partnership with SCIEX will enhance product sales, valuation very attractive---Buy by Zacks
- PBIO: First purchase order received for HT48 system, expecting continued revenue growth in 4Q14 and beyond; valuation very attractive- --Outperform by Zacks
- PBIO: Product and service revenue continued to grow in 3Q16, partnership with SCIEX will enhance product sales, valuation very attractive by Zacks
- PBIO: Record revenue reported for 1Q15, expecting significant revenue growth in 2015 and beyond; valuation very attractive---Buy by Zacks
- PBIO: revenue continued to grow in 2Q16, great achievements in PIPE financing, partnership with SCIEX will enhance product sales, valuation very attractive by Zacks
- PBIO: two new products will be launched soon, expecting continued revenue growth in 4Q13 and fiscal 2014; valuation very attractive---Outperform. by Zacks
- Raising 2012 Estimate and Target Price by Zacks
- Raising Recommendation by Zacks
- Record First Quarter Net Earnings by Zacks
- Second Quarter Displays Strong Sequential Growth in Merchant Card and Cash Flow Businesses by Zacks
- Second Quarter Results by Zacks
- Third Quarter Results by Zacks
- Third Quarter Results by Zacks
- Unique preventive and therapeutic HIV/AIDS vaccine development technology with candidates in efficacy studies by Zacks
- $10M Raise Gets SNWV To PMA Submission by Zacks
- 1Q13 product sales grew 35% year over year; total revenue expected to surpass $2 million in 2013; valuation very attractive - Outperform by Zacks
- 90% Enrollment Complete. $10M Financing Gets SNWV to PMA Submission by Zacks
- Balance Sheet is further Boosted by Private Placement by Zacks